Last reviewed · How we verify

Whole Body PET Baseline with 11C Rolipram

National Institute of Mental Health (NIMH) · Phase 1 active Small molecule Quality 0/100

Whole Body PET Baseline with 11C Rolipram is a Small molecule drug developed by National Institute of Mental Health (NIMH). It is currently in Phase 1 development.

At a glance

Generic nameWhole Body PET Baseline with 11C Rolipram
SponsorNational Institute of Mental Health (NIMH)
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Whole Body PET Baseline with 11C Rolipram

What is Whole Body PET Baseline with 11C Rolipram?

Whole Body PET Baseline with 11C Rolipram is a Small molecule drug developed by National Institute of Mental Health (NIMH).

Who makes Whole Body PET Baseline with 11C Rolipram?

Whole Body PET Baseline with 11C Rolipram is developed by National Institute of Mental Health (NIMH) (see full National Institute of Mental Health (NIMH) pipeline at /company/national-institute-of-mental-health-nimh).

What development phase is Whole Body PET Baseline with 11C Rolipram in?

Whole Body PET Baseline with 11C Rolipram is in Phase 1.

What are the side effects of Whole Body PET Baseline with 11C Rolipram?

Common side effects of Whole Body PET Baseline with 11C Rolipram include Pain in extremity, Headache, Panic attack.

Related